Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Elamipretide, Mitochondria targeting tetrapeptide
A cell permeable tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae and improving bioenergetics, the first drug to directly target mitochondria.

A cell permeable peptide that homes to the inner mitochondrial membrane and binds cardiolipin, stabilizing the energy machinery and cutting oxidative stress.
Mitochondrial disease
Cardiolipin stabilization
Extrapolative
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Reid Thompson W, et al.
In the open label extension, elamipretide was well tolerated with sustained improvements in functional assessments and cardiac function.
FDA accelerated approval (Sept 2025) for Barth syndrome, the first drug to directly target mitochondria. The randomized crossover portion of TAZPOWER (12 subjects) did NOT meet its primary endpoints; approval rested on the open label extension showing improved knee extensor strength. Longevity/anti aging uses are entirely extrapolative.
Most common adverse event was injection site reactions (treatable). Continued approval is contingent on verifying clinical benefit.
FDA approved (rare disease, Stealth BioTherapeutics). In off label/wellness use it would be WADA prohibited under S0.
Daily subcutaneous (40 mg in trials).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.